Subsequent to our studies carried in 1977-79, demonstrating that the administration of syngeneic antiidiotypic antibodies (i.e. anti-460Id) caused the expansion of clones producing 460Id+ anti- TNP antibodies, numerous experimental data showed that anti-Id antibodies can be used as antigen surrogates or as idiotype vaccines. Several aspects underscore the attraction of using idiotypic vaccines in viral infections caused by viruses exhibiting genetic variations since it is envisioned that anti-idiotypic antibodies specific for a cross-reactive idiotype expressed on clones for various subtypes of virus could be broader than classical formalin inactivated vaccines.
The aims of our proposal are: 1. To select anted antibodies against monoclonal antibodies specific for hemagglutinin or neuraminidase of various subtypes of type A influenza virus or sequential virus variants and to investigate their ability to elicit an anti-hemagglutinin or neuraminidase response. The structure of variable region genes encoding the antibodies as will as of hemagglutinin gene of sequential variants will be studied to understand the molecular basis of mimicry of viral antigens by antibodies. 2. To produce monoclonal antibodies against envelope glycoprotein gp120, gp41 of HLTV-III and against a synthetic peptide corresponding to amino acid sequence 735 to 752 of the precursor envelope glycoprotein of HLTV-III virus. Antibodies specific for glycoproteins, synthetic peptides of HIV or CD4 of T cells will be used to produce anted antibodies which will be tested in experimental systems for their ability to elicit antiviral immunity. 3. To prepare hybrid molecules made up of murine V region of anted antibodies and constant region of human Ig in order to minimize the harmful immune reactions which could occur subsequent to the administration of foreign antibodies in humans.

Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Isobe, H; Moran, T; Li, S et al. (1995) Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant. J Exp Med 181:203-13
Zaghouani, H; Anderson, S A; Sperber, K E et al. (1995) Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein. Proc Natl Acad Sci U S A 92:631-5
Rodrigues, M; Li, S; Murata, K et al. (1994) Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol 153:4636-48
Zaghouani, H; Steinman, R; Nonacs, R et al. (1993) Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science 259:224-7
Macri, P; Gordon, J W (1993) Transgenic animals as tools for investigating hepatocyte gene regulation and liver disease. Prog Liver Dis 11:1-25
Kuzu, H; Kuzu, Y; Zaghouani, H et al. (1993) In vivo priming effect during various stages of ontogeny of an influenza A virus nucleoprotein peptide. Eur J Immunol 23:1397-400
Kuzu, Y; Kuzu, H; Zaghouani, H et al. (1993) Priming of cytotoxic T lymphocytes at various stages of ontogeny with transfectoma cells expressing a chimeric Ig heavy chain gene bearing an influenza virus nucleoprotein peptide. Int Immunol 5:1301-7
Brumeanu, T D; Kohanski, R; Bona, C A et al. (1993) A sensitive method to detect defined peptide among those eluted from murine MHC class II molecules. J Immunol Methods 160:65-71
Li, S; Polonis, V; Isobe, H et al. (1993) Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol 67:6659-66
Li, S; Rodrigues, M; Rodriguez, D et al. (1993) Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A 90:5214-8

Showing the most recent 10 out of 22 publications